Moleculin Biotech CFO acquires 362 shares on conversion
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Moleculin Biotech, Inc. (MBRX) Chief Financial Officer Jonathan P. Foster exercised 362 restricted stock units into 362 common shares on November 16, 2026; the units convert one-for-one. 89 shares were withheld for payment of taxes at $7.14 per share upon vesting. The table reports 70,492 restricted stock units following the derivative transaction. No Rule 10b5-1 plan is reported.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units F1, F3, F4 | 362 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 362 | -- | -- |
| Tax Withholding | Common Stock F2 | 89 | $7.14 | $635.46 |
Footnotes (4)
- F1. Restricted stock units convert into common stock on a one-for-one basis.
- F2. Shares withheld for payment of taxes upon vesting of restricted stock unit awards.
- F3. The restricted stock unit set forth in this table vests as follows: (i) 50% on grant; and (ii) 50% in 18 equal installments over 18 months.
- F4. Each restricted stock unit represents a contingent right to receive one shares of Company common stock.
Key Figures
Key Terms
Restricted stock units financial
contingent right financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What was the vesting schedule for Jonathan P. Foster's MBRX restricted stock units?
AI-generated analysis. How Rhea-AI works. Not financial advice.